Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.
Annabelle Ayame OkadaKanji TakahashiMasahito OhjiSungChul Charles MoonTobias MachewitzKoji Sasakinull nullPublished in: Advances in therapy (2022)
ClinicalTrials.gov identifier, NCT02305238.